Technology
Upcoming Earnings
Health

Eidos Therapeutics

$20.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (1.02%) Today
+$0.21 (1.02%) Today

Why Robinhood?

You can buy or sell EIDX and other stocks, options, ETFs, and crypto commission-free!

About

Eidos Therapeutics, Inc. engages in biotechnology and scientific developments. The company was founded by Graef Isabella and Alhamadsheh Mamoun and is headquartered in San Francisco, CA.

Employees
11
Headquarters
San Francisco, California
Founded
Market Cap
758.10M
Price-Earnings Ratio
Dividend Yield
Average Volume
173.42K
High Today
$21.26
Low Today
$20.04
Open Price
$20.30
Volume
40.82K
52 Week High
$24.75
52 Week Low
$8.89

Collections

Technology
Upcoming Earnings
Health
Biotechnology
Therapy
2018 IPO
US
North America

News

StreetInsiderFeb 27

Eidos Therapeutics (EIDX) Begins Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

Eidos Therapeutics, Inc. (NASDAQ: EIDX) today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The design of the ATTRibute-CM study, which incorporates feedback from FDA, includes two potentially registrational endpoints. In Part A, benefit in change from baseline in 6-minute walk distance (6MWD) will be evaluated at 12 months, potentially accelerating the time to registration. In Part B, red...

265

Earnings

-$0.29
-$0.28
-$0.26
-$0.25
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.25 per share
Actual
Expected Today, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.